CN104334547B - 作为kv3抑制剂的三唑类 - Google Patents

作为kv3抑制剂的三唑类 Download PDF

Info

Publication number
CN104334547B
CN104334547B CN201380026338.8A CN201380026338A CN104334547B CN 104334547 B CN104334547 B CN 104334547B CN 201380026338 A CN201380026338 A CN 201380026338A CN 104334547 B CN104334547 B CN 104334547B
Authority
CN
China
Prior art keywords
methyl
alkyl
epoxide
phenyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380026338.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104334547A (zh
Inventor
A·马拉斯科
G·阿尔瓦罗
A·德科
D·汉普雷希特
P·丹布罗索
S·托马西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1209019.7A external-priority patent/GB201209019D0/en
Priority claimed from GBGB1209020.5A external-priority patent/GB201209020D0/en
Priority claimed from GBGB1209013.0A external-priority patent/GB201209013D0/en
Priority claimed from GBGB1222393.9A external-priority patent/GB201222393D0/en
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of CN104334547A publication Critical patent/CN104334547A/zh
Application granted granted Critical
Publication of CN104334547B publication Critical patent/CN104334547B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/48—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of 2,2-dimethylcyclopropane rings, e.g. nitrile of chrysanthemumic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/313—Compounds having groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380026338.8A 2012-05-22 2013-05-22 作为kv3抑制剂的三唑类 Expired - Fee Related CN104334547B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1209020.5 2012-05-22
GBGB1209019.7A GB201209019D0 (en) 2012-05-22 2012-05-22 Novel compounds
GB1209013.0 2012-05-22
GBGB1209020.5A GB201209020D0 (en) 2012-05-22 2012-05-22 Novel compounds
GBGB1209013.0A GB201209013D0 (en) 2012-05-22 2012-05-22 Novel compounds
GB1209019.7 2012-05-22
US201261702337P 2012-09-18 2012-09-18
US61/702,337 2012-09-18
GB1222393.9 2012-12-12
GBGB1222393.9A GB201222393D0 (en) 2012-12-12 2012-12-12 Novel compounds
PCT/GB2013/051347 WO2013175215A1 (en) 2012-05-22 2013-05-22 Triazoles as kv3 inhibitors

Publications (2)

Publication Number Publication Date
CN104334547A CN104334547A (zh) 2015-02-04
CN104334547B true CN104334547B (zh) 2017-06-06

Family

ID=49623224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380026338.8A Expired - Fee Related CN104334547B (zh) 2012-05-22 2013-05-22 作为kv3抑制剂的三唑类

Country Status (6)

Country Link
US (4) US9422252B2 (cg-RX-API-DMAC10.html)
EP (1) EP2852589B1 (cg-RX-API-DMAC10.html)
JP (1) JP6240667B2 (cg-RX-API-DMAC10.html)
CN (1) CN104334547B (cg-RX-API-DMAC10.html)
BR (1) BR112014028991A2 (cg-RX-API-DMAC10.html)
WO (1) WO2013175215A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
BR112014027644A2 (pt) * 2012-05-09 2017-06-27 Bayer Cropscience Ag 5-halogenopirazol-indanil-carboxamidas
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
CN104334547B (zh) * 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
WO2015095442A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Piperidinyloxy lactone orexin receptor antagonists
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
WO2019246454A1 (en) * 2018-06-20 2019-12-26 Neuropore Therapies, Inc. Method of treating a condition associated with neurodegeneration using inhibitors of oat3
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
PL3867247T3 (pl) 2018-10-16 2024-12-09 Autifony Therapeutics Limited Nowe związki
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
KR20260110250A (ko) * 2018-11-30 2026-07-14 오츠카 세이야쿠 가부시키가이샤 간질의 치료를 위한 헤테로시클릭 화합물
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
CN101600689A (zh) * 2006-12-15 2009-12-09 Irm责任有限公司 作为大麻素受体1活性抑制剂的化合物和组合物
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US6002016A (en) 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
US5607932A (en) * 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
MX9708802A (es) 1995-05-17 1998-02-28 Du Pont Amidas ciclicas fungicidas.
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
PL324291A1 (en) 1995-06-20 1998-05-11 Du Pont Anthropodicidal and fungicidal cyclic amides
AU3889097A (en) 1996-08-01 1998-02-25 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
US5728834A (en) 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
CZ184599A3 (cs) 1996-11-26 1999-09-15 E. I. Du Pont De Nemours And Company Methylem substituované fungicidy a artropodicidy
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
BR0012697A (pt) 1999-07-23 2002-04-09 Shionogi & Co Inibidores da diferenciação de th2
US20030149061A1 (en) 2000-04-04 2003-08-07 Yoshitaka Nishihara Oily compositions containing highly fat-soluble drugs
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
JPWO2003048134A1 (ja) 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
AU2003210916B9 (en) 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
AU2003206021A1 (en) 2003-02-20 2004-09-09 Ranbaxy Laboratories Limited Derivatives of azasugars as anticancer agents
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
WO2005085226A1 (en) * 2004-03-10 2005-09-15 Janssen Pharmaceutica N.V. Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
AR052342A1 (es) 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US8541572B2 (en) 2008-11-10 2013-09-24 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
KR20110094352A (ko) 2008-12-22 2011-08-23 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
TW201144298A (en) 2009-12-14 2011-12-16 Hoffmann La Roche Heterocyclic antiviral compounds
EP2616443A1 (en) 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
KR101862375B1 (ko) * 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
PL2788339T3 (pl) 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600689A (zh) * 2006-12-15 2009-12-09 Irm责任有限公司 作为大麻素受体1活性抑制剂的化合物和组合物
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Also Published As

Publication number Publication date
US10611735B2 (en) 2020-04-07
US20190071405A1 (en) 2019-03-07
WO2013175215A1 (en) 2013-11-28
US20160318882A1 (en) 2016-11-03
US9422252B2 (en) 2016-08-23
BR112014028991A2 (pt) 2017-06-27
US10160730B2 (en) 2018-12-25
CN104334547A (zh) 2015-02-04
US20200172496A1 (en) 2020-06-04
EP2852589A1 (en) 2015-04-01
US11180461B2 (en) 2021-11-23
JP6240667B2 (ja) 2017-11-29
US20150111910A1 (en) 2015-04-23
JP2015520764A (ja) 2015-07-23
EP2852589B1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
US11180461B2 (en) Triazoles as Kv3 inhibitors
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
US11541052B2 (en) Compounds
CN103974944B (zh) 用作kv3抑制剂的乙内酰脲衍生物
KR20120107490A (ko) 이미다졸리딘디온 유도체
TWI827706B (zh) 新穎化合物
JP2019502696A (ja) Ｋｖ３チャネルのヒダントインモジュレーター
CN117751119A (zh) 钾通道调节剂
JP7522203B2 (ja) Ｋｖ３モジュレーター
RU2830279C2 (ru) Новые соединения
HK40059039A (en) Novel compounds
HK40059039B (en) Novel compounds
EA049235B1 (ru) Модуляторы kv3
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil
HK1203072B (en) Hydantoin derivatives useful as kv3 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170606

Termination date: 20210522